Edgewise Therapeutics (EWTX) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Precigen (PGEN) over the past year, gaining 155.6% versus a gain of 136.0%. Over five years, EWTX leads with a +121.1% price change compared with +63.4% for PGEN. Edgewise Therapeutics is the larger company by market cap ($4.26 billion vs $2.72 billion), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | PGEN |
|---|---|---|
| Share price | $39.23 | $7.60 |
| Market cap | $4.26B | $2.72B |
| 1-day change | -0.86% | +0.80% |
| YTD return | +58.09% | +81.82% |
| 1-year return | +155.57% | +136.02% |
| 5-year return | +121.14% | +63.44% |
| EPS (TTM) | $-1.85 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.68M |
| Revenue growth (YoY) | — | +146.73% |
| Net income (latest FY) | $-167.79M | $-250.64M |
| Operating margin | — | -1141.13% |
| Net margin | — | -2588.21% |
| 52-week high | $48.51 | $8.98 |
| 52-week low | $14.25 | $2.99 |
| Distance from 52-week high | -19.13% | -15.37% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +34.13% | +79.61% |
| Average volume | 1.34M | 5.03M |
| Shares outstanding | 108.60M | 358.04M |
| Employees | 127 | 160 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed PGEN by 19.5 percentage points over the past year.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 127 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
EWTX vs PGEN FAQ
Which is bigger, Edgewise Therapeutics or Precigen?
Edgewise Therapeutics (EWTX) is larger, with a market capitalization of $4.26B compared with $2.72B for Precigen (PGEN).
Which stock has performed better over the past year, EWTX or PGEN?
EWTX returned +155.57% over the past 12 months, compared with +136.02% for PGEN (price return, excluding dividends). Past performance does not predict future results.
Are Edgewise Therapeutics and Precigen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.